| Authors: |
Draghia-Akli R; Research and Development, Novavax, Inc., Gaithersburg, Maryland, USA.; INTREPID Alliance, Cambridge, Massachusetts, USA., Hill NM; INTREPID Alliance, Cambridge, Massachusetts, USA., Altevogt B; KKCM Consulting Inc., Silver Springs, Massachusetts, USA., Bradley K; INTREPID Alliance, Cambridge, Massachusetts, USA.; Infectious Disease Discovery, F. Hoffmann-La Roche, Basel, Switzerland., Chibale K; INTREPID Alliance, Cambridge, Massachusetts, USA.; Holistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Cape Town, South Africa.; Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Cihlar T; INTREPID Alliance, Cambridge, Massachusetts, USA.; Virology, Gilead Sciences, Inc, Foster City, California, USA., Clinch B; INTREPID Alliance, Cambridge, Massachusetts, USA.; Pottershealth Associates, Ltd., Welwyn, Hertfordshire, England., Demarest JF; INTREPID Alliance, Cambridge, Massachusetts, USA.; Mountaineer Bio, LLC, Durham, North Carolina, USA., Neyts J; INTREPID Alliance, Cambridge, Massachusetts, USA.; Department of Microbiology, Immunology and Transplantation, University of Leuven (KU Leuven), Leuven, Belgium. |
